RecruitingPhase 3NCT06937086
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Sponsor: Eli Lilly and Company
New York, NY · Yonkers, NY · +34 more sites